Pharma segment volume growth driven by new drug-device combination product launches and respiratory therapy adoption (inhalers, nasal sprays)
Beauty segment demand tied to prestige cosmetics and fragrance market health, particularly in Europe and Asia-Pacific
Raw material cost inflation (polypropylene, elastomers, aluminum) and ability to pass through pricing to customers
New product innovation pipeline, particularly in active material science (preservative-free formulations) and sustainable packaging solutions
moderate - Pharma segment (~50% of revenue) demonstrates counter-cyclical characteristics as prescription drug demand remains stable through economic cycles, providing earnings stability. Beauty segment shows pro-cyclical sensitivity to discretionary consumer spending, particularly in prestige cosmetics and fragrance categories which contract 5-10% during recessions. Food/beverage segment is largely non-cyclical. Overall company revenue typically declines 2-4% in recession years, significantly less than broader industrials.
Rising interest rates create modest headwinds through higher financing costs on the company's $1.5B debt load (Debt/Equity of 0.57), adding approximately $15-20M in annual interest expense per 100bps rate increase. However, AptarGroup's investment-grade credit profile and moderate leverage limit refinancing risk. Valuation multiples compress modestly as rates rise, as the stock trades at premium multiples (12.5x EV/EBITDA) typical of quality healthcare industrials. Demand-side impact is minimal as pharma customers are rate-insensitive and beauty demand shows weak correlation to rate changes.
Shift toward sustainable packaging driving R&D investment requirements in recyclable materials and refillable systems, potentially compressing margins if customers resist price increases for eco-friendly solutions
Regulatory changes in pharmaceutical delivery devices (FDA combination product guidelines, European Medical Device Regulation) requiring continuous compliance investments and potential product re-validation costs
Patent cliffs in respiratory drugs (generic inhaler competition) reducing demand for branded drug delivery systems, though offset by biologics growth requiring specialized delivery
quality growth - Attracts investors seeking durable competitive advantages through regulatory moats and customer switching costs, with modest but consistent growth (5-7% revenue CAGR) and strong cash generation (FCF yield 3.2%). Dividend yield of approximately 1.5% appeals to total return investors rather than pure income seekers. The pharma/healthcare exposure provides defensive characteristics while beauty segment adds growth optionality. Premium valuation (12.5x EV/EBITDA vs. 10x for broader industrials) reflects quality bias.
No analyst coverage available for this stock.
Trend
-3.6% vs SMA 50 · -8.6% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ATR News
Unable to load news
About
aptar is a leading global supplier of a broad range of innovative dispensing systems for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food, and beverage markets. aptar is headquartered in crystal lake, illinois, with manufacturing facilities in north america, europe, asia and south america. for more information, visit www.aptar.com.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
ATR◀ | $119.02 | -3.77% | $7.7B | 19.7 | +542.3% | 1039.9% | 1500 |
| $397.67 | +0.41% | $2.1T | 28.7 | +3296.8% | 4510.0% | 1500 | |
| $91.95 | +0.10% | $316.0B | 14.1 | +318.8% | 1510.7% | 1500 | |
| $131.46 | -0.32% | $305.1B | 22.6 | +586.3% | 1305.9% | 1500 | |
| $184.74 | -1.40% | $286.4B | 27.2 | +862.9% | 1745.9% | 1500 | |
| $146.57 | -0.87% | $279.7B | 21.0 | +597.3% | 2564.4% | 1500 | |
| $88.98 | -1.86% | $251.9B | 14.4 | -591.0% | 668.4% | 1500 | |
| Sector avg | — | -1.10% | — | 21.1 | +801.9% | 1906.4% | 1500 |